Crohn's Disease research hub

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

This study looks at a new drug, TAK-279, for people aged 18-75 with Crohn's disease that isn't well-controlled. We want to see if it reduces gut inflammation and is safe, compared to a dummy drug. It lasts about one year.

Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

This study is investigating a new medication called AZD7798 for people with Crohn's disease who have had an ileostomy. We want to see if it's safe, well-tolerated, and helps heal the gut lining compared to a dummy drug.

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

This study looks at new medications for adults with moderate to severe Crohn's disease. Researchers want to see how well these 'targeted therapies' work and if they cause side effects, to find better ways to manage the condition.

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

This study looks at how well a medicine called guselkumab works for adults with moderate to severe Ulcerative Colitis or Crohn's Disease in the UK. Researchers want to see its real-world benefits and how different groups of patients respond.

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

This study is looking at a new way to give risankizumab, a medicine for Crohn's disease, as an injection under the skin. It aims to see how well it works and if it's safe for adults with moderate to severe Crohn's disease.

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

This study is testing a new medicine, SAR442970, for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and helps improve symptoms compared to a dummy pill. It's a key step in developing new treatments.

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

This study is looking at a new treatment called risankizumab for children and young people aged 2 to 17 with Crohn's disease that hasn't responded well to other medicines. Scientists want to see if it's safe, helps their symptoms, and how it works in their bodies.

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

This study looks at combining two medicines, vedolizumab and upadacitinib, for adults with moderate to severe Crohn's Disease. It aims to see if this combination better reduces bowel inflammation and ulcers compared to vedolizumab alone, and to check its safety.

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

This study looks at a new medicine called guselkumab for children and teenagers aged 2 to 17 with moderately to severely active Crohn's disease. It checks how well the medicine works after a year in those who responded early on.

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.

MRE Predictors of Disease Relapse After Stopping Biologics

This study looks at whether a special MRI scan, called MRE, can help predict if Crohn's disease will come back quickly after people stop taking certain medications (biologics). It aims to help doctors decide who can safely stop these treatments.

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

This study is testing a new medicine called Upadacitinib for children and teenagers with Crohn's disease. It's for those whose current treatments aren't working well. We want to see if it's safe and helps them feel better.

Vibration Exercise for Crohn's to Observe Response

This study looks at whether a special type of exercise, called whole body vibration, can help people with Crohn's disease feel better. We want to see if standing on a vibrating plate for a short time can improve quality of life and reduce symptoms like tiredness.

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

This study looks at how well a medicine called Humira works and how safe it is for children aged 6 to 17 with Crohn's disease. It also compares Humira to other common treatments like azathioprine, 6-mercaptopurine, or methotrexate, watching patients over a long time.

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

This study looks at the long-term safety of a medicine called vedolizumab for children and young people with Crohn's disease or ulcerative colitis. It's for those who have already taken part in a previous study with vedolizumab.

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

This study is looking at a new medicine called mirikizumab for children and teenagers with Crohn's disease. It wants to find out if it's safe, works well, and how the body handles it. It will involve those who haven't responded well to other treatments.

Evaluation of the efficacy of topical treatment with budesonide in children with Crohn's disease located in the esophagus and/or stomach and/or duodenum - BETHESDa

This study, called BETHESDa, is looking into how well a medicine called budesonide works for children with Crohn's disease that affects their food pipe, stomach, or the first part of their small bowel. They're checking if it can make visible signs of the disease disappear.

Fecal microbiota transplantation in patients receiving infliximab and vedolizumab for ulcerative colitis: A randomized controlled trial

This study looks at how well a treatment called faecal microbiota transplant (FMT) works with other medicines (infliximab and vedolizumab) for people with ulcerative colitis. The aim is to see if this combination helps people feel better and stay in remission without needing steroids.

A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohn’s disease or ulcerative colitis

This study looks at a new medicine called balinatunfib for adults with Crohn's disease or ulcerative colitis. It mainly checks for any side effects and how safe it is over a longer time. It also looks at if the treatment helps improve symptoms and gut health.

Methotrexate in paediatric and adolescent Crohn’s disease: an observational study

This study looks at how well a medicine called methotrexate works for young people with Crohn's disease over a year. It checks how much of the medicine stays in the body and if patients need to stop using it due to side effects or if it's not helping enough.

OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE

This study looks at how well a medicine called guselkumab works for people with Crohn's disease. Researchers want to see if it can help people stay well without steroids and reduce a marker of gut inflammation over 48 weeks.

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

This study looks at a medicine called Mirikizumab for children and teenagers aged 2 to 19 with Ulcerative Colitis or Crohn's Disease. It checks how well the medicine works over a long time to help manage these conditions.

A phase IIa, open label, Single-centre study to assess the initial antifibrotic efficacy, safety, tolerability, pharmacokinetic and pharmacodynamic profile of MBF-118 in Crohn’s disease patients with stenosis.

A Phase 0 Open Label Positron Emission Tomography Study to Assess the Biodistribution and Binding Characteristics of [11C]AZ14132516 Following Administration to Healthy Participants

A Phase 1 Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Mild to Moderate Crohn's Disease

A phase II, national, multicenter, uncontrolled and open trial to evaluate the feasibility and safety of lamparoscopic administration of allogenic mesenchymals stem cell (adMSC) extracted by lipoaspirate from healthy patients, for the treatment of patients with inflammatory bowel strictures associated with Crohn's disease. SM

PET study of changes in [11C]AZ14132516 uptake following administration of AZD7798 to healthy participants and patients with Crohn’s disease

A Study to Learn How Different Manufactured Products of the Study Medicine Called Ritlecitinib are Taken up Into the Blood in Healthy Adults When Taken on an Empty Stomach or When Taken With a Meal in Healthy Adults.

A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.

An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.

PET study of changes in [11C]AZ14132516 uptake following administration of multiple AZD7798 doses to patients with Crohn’s disease.

Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled trial

A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease

C5041006 (APD334 202 or APD334-202EU): A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

A Prospective Multicenter Randomized Controlled, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn’s Disease ( Direct-CD)

Treatment of refractory Crohn's disease lesions by local injection of mesenchymal stem cells

A study to investigate whether novel vaccines can improve Crohn's disease by targeting a bacterium thought to contribute to the condition

This study is testing two new vaccines for Crohn's disease. Researchers believe these vaccines could help by targeting a specific common bacterium. It's a Phase II trial looking at how well they work, their safety, and how the body reacts in adults with active Crohn's.